Efavirenz: A pharmacoeconomic review of its use in HIV infection

PharmacoEconomics

Volumn 19, Issue 4, 2001, Pages 421-436

  Plosker, G L ^a   Perry, C M ^a   Goa, K L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INDINAVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

DRUG COST; DRUG EFFICACY; DRUG MIXTURE; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; PRIORITY JOURNAL; REVIEW; VERTIGO; VIRUS LOAD;

EID: 0035047213     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119040-00009     Document Type: Review

References (83)

1. Efavirenz
2. Efavirenz: Shifting the HAART paradigm in adult HIV-1 infection
3. Efavirenz in the management of HIV infection
4. The AIDS epidemic: Considerations for the 21st century
5. A comprehensive plan for managed care of patients infected with human immunodeficiency virus
6. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs
7. Understanding the clinical and economic outcomes of HIV therapy: The Johns Hopkins HIV Clinical Practice Cohort
8. The economic costs of caring for people with HIV infection and AIDS in England and Wales
9. Lifetime costs of treating-HIV infected patients using a protease inhibitor
10. Comparative health care costs in a regional HIV/AIDS population
11. Costs of HIV medical care in the era of highly active antiretroviral therapy
12. Trends in costs of care for patients with HIV
13. Economic impact of delaying or preventing AIDS in persons with HIV
14. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA panel
15. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
16. A phase II, double-blind, placebo-control, dose-ranging study to assess the antiretroviral activity & safety of efavirenz (EFV, SUSTIVA, DMP266) in combination with open-label zidovudine (ZDV) w/ lamivudine (3TC) at >48 weeks
17. La Francilienne, a pilot open-label study to evaluate safety and efficacy of a potent combination therapy without protease inhibitor (3TC+ZDV+ abacavir+ efavirenz) in antiretroviral therapy naive adults: Preliminary results
18. Efavirenz (EFV) in combination with stavudine (D4T) and didanosine (DDI) or lamivudine (3TC) is well tolerated and efficacious in the majority of patients treated
19. Efavirenz versus nevirapine: Efficacy and effects on blood lipids in PI-sparing regimens
20. Initial effectiveness and tolerability of nelfinavir (NFV) in combination with efavirenz (EFV, SUSTIVA, DMP 266) in antiretroviral therapy naive or nucleoside analogue experienced HIV-1 infected patients: Characterization in a phase II, open-label, multi-center study at greater than 36 weeks (Study DMP 266-024)
21. A pilot study of FTC + ddI + efavirenz in treatment-naive HIV-infected adult: A potent and convenient once-a-day HAART (ANRS 091 Trial)
22. Switch from protease inhibitor containing regimens with stavudin (D4T) and lamivudin(3TC) to D4T, 3TC and efavirenz (EFV) in patients with sustained viral suppression
23. A phase III, double-blind, placebo-controlled, multicenter study to determine the effectiveness and tolerability of the combination of efavirenz (EFV, SUSTIVA TM, DMP 266) and indinavir (IDV) versus IDV in HIV-1-infected patients receiving nucleoside analogue therapy (NRTI) at 24 weeks (study DMP 266-020)
24. A phase II, double-blind, placebo-controlled, multi-center study to determine the effectiveness and tolerability of the combination of efavirenz (EFV, SUSTIVA, DMP 266) and indinavir (IDV) versus IDV in HIV-1 infected patients receiving nucleoside analogue (NRTI) therapy at >36 weeks
25. ACTG 364: Virologic efficacy of nelfinavir (NFV) and/or efavirenz (EFV) in combination with new nucleoside analogs in nucleoside experienced subjects
26. ACTC 364- nelfinavir (NFV) and/or efavirenz (EFV) in combination with new NRTIs in nucleoside experienced subjects (Subj): Week-48 ultrasensitive (US) HIV RNA results
27. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1
28. A phase III, multicenter, randomized, open label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 48 weeks (Study DMP 266006) macrolide subinhibitory concentrations
29. Longer time-to-treatment failure and durability of response with efavirenz + ZDV + 3TC: First analysis of full 1266 patient cohort from study 006
30. Efavirenz (EFV) + zidovudine (ZDV) + lamivudine (3TC) provides superior long-term antiretroviral activity and tolerability versus IDV + ZDV + 3TC at 72 weeks: Results from a phase III, multicenter, randomized, open-label study in 450 patients (Study DPC266-006 initial cohort)
31. Low two year risk of virologic failure with first regimen HAART
32. Durable HIV suppression and tolerability with efavirenz (EFV) + indinavir (IDV): Results at 132 weeks (Study 003-Cohort IV)
33. Durable clinical anti-HIV-1 activity at 84 weeks and tolerability for efavirenz (EFZ) in combination with indinavir (IDV)
34. Salvage therapy with efavirenz
35. Durability of abacavir/amprenavir/efavirenz combination salvage therapy - Preliminary 48-week response (CNA2007)
36. Salvage therapy with non nucleoside reverse transcriptase inhibitors (NNRTI) in patients failing protease inhibitors containing regimens
37. Effectiveness of adefovir+abacavir+efavirenz as salvage therapy for patients with documented virologic failure to other combination antiretroviral drug regimens
38. Salvage therapy with abacavir, amprenavir, and efavirenz in subjects with plasma HIV- 1 RNA > 500 copies/mL despite protease inhibitor (PI) therapy
39. Efavirenz and adefovir dipivoxil-based salvage in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
40. Efficacy and safety of abacavir+efavirenz plus background combination therapy as a salvage regimen in HIV-infected individuals
41. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors
42. Abacavir/efavirenz/adefovir salvage regimen for refractory HIV disease
43. Different efficacy of efavirenz-containing rescue regimens for patients failing protease inhibitors depending on previous nevirapine experience
44. sgc, indinavir (IDV) or nelfinavir (NFV) in combination with amprenavir (APV), abacavir (ABC), efavirenz (EFZ) and adefovir (ADV) in patients (Pts) with protease inhibitor (PI) failure
45. Potential adverse experiences associated with efavirenz
46. Antiretrovirals
47. Economic analysis of initial HIV treatment: Efavirenz- versus indinavir-containing triple therapy
48. Cost comparison of efavirenz (EFV) and indinavir (IDV) combination therapies for HIV infection
49. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
50. AVANTI2. A randomised double blind, comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs. AZT/3TC/indinavir in anti-retroviral naive patients: 100 week data
51. + lymphocytes as prognostic markers for HIV-1 infection
52. + cell counts in HIV-infected patients
53. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter
54. Indinavir: A review of its use in the management of HIV infection
55. Choosing the best initial therapy for HIV-1 infection
56. United Kingdom AIDS survival in adults
57. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
58. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. Swiss HIV Corhort Study
59. Changing patterns of mortality across Europe in patients infected with HIV-1
60. Hope for HIV patients: News from the 12th International Conference on HIV and AIDS
61. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens
62. Decreased medical expenditures for care of HIV-seropositive patients: The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center
63. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality
64. Improved survival time and CD4 slope associated with recent advances in HIV antiretroviral therapy
65. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy
66. HAART reduced overall costs of H1V care at DVAMC-Denver
67. Impact of aggressive management of HIV infection on clinical outcome and cost of care within a health maintenance organization
68. The impact of new antiretroviral regimes on HIV-associated hospital admissions and deaths
69. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
70. New principals for treatment - How does it affect the costs for HIV care?
71. Recent advances in antiviral therapy (ARV) for HIV can result in lower total costs - 3 year analysis
72. Economic impact of protease inhibitors on HIV treatment
73. The changing economics of HIV care
74. Economic impact of HIV care in a managed care environment
75. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients
76. 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
77. Health economics in HIV disease: A review of the European literature
78. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
79. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection
80. Assessment of quality of life, adherence and emotional status in patients treated with efavirenz